Evidence map›Paper›PMID 37737279›Full record

ArticleCancer gene therapy2023

Correction: α-Catenin acetylation is essential for its stability and blocks its tumor suppressor effects in breast cancer through Yap1.

Yuxi Yang, Shujing Li, Yulin Li, Linlin Lv, Dongman Ye, Jie Kang, Tao Yu, Yaming Wang, Huijian Wu

Open access · bronzeAbstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 71% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yuxi Yang *School of Bioengineering & Key Laboratory of Protein Modification and Disease, Liaoning Province, Dalian University of Technology, Dalian, China.
Shujing Li *School of Bioengineering & Key Laboratory of Protein Modification and Disease, Liaoning Province, Dalian University of Technology, Dalian, China.ORCID http://orcid.org/0000-0002-8643-1244
Yulin LiSchool of Bioengineering & Key Laboratory of Protein Modification and Disease, Liaoning Province, Dalian University of Technology, Dalian, China.
Linlin LvSchool of Bioengineering & Key Laboratory of Protein Modification and Disease, Liaoning Province, Dalian University of Technology, Dalian, China.
Dongman YeCancer Hospital of Dalian University of Technology, Shenyang, China.
Jie KangSchool of Bioengineering & Key Laboratory of Protein Modification and Disease, Liaoning Province, Dalian University of Technology, Dalian, China.
Tao YuCancer Hospital of Dalian University of Technology, Shenyang, China. yutao@cancerhosp-ln-cmu.com.
Yaming WangThe first affiliated Hospital of Dalian Medical University, Dalian, China. dlwym@mail.dlut.edu.cn.ORCID http://orcid.org/0009-0000-4455-3123
Huijian WuSchool of Bioengineering & Key Laboratory of Protein Modification and Disease, Liaoning Province, Dalian University of Technology, Dalian, China. wuhj@dlut.edu.cn.ORCID http://orcid.org/0000-0001-5257-0089
Dalian University of Technology · CNDalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37737279
OpenAlexW4386944126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.